Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1200 PAGE MILL RD PALO ALTO CA 94304 |
Tel: | N/A |
Website: | https://kodiak.com |
IR: | See website |
Key People | ||
Victor Perlroth Chairman of the Board, President, Chief Executive Officer, Co-Founder | John A. Borgeson Chief Financial Officer, Executive Vice President, Secretary |
Business Overview |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF. |
Financial Overview |
For the fiscal year ended 31 December 2023, Kodiak Sciences Inc revenues was not reported. Net loss decreased 22% to $260.5M. Lower net loss reflects Research and development decrease of 22% to $162.3M (expense), Stock-based Compensation in R&D decrease of 26% to $44M (expense), Interest income increase from $7.1M to $16.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$6.39 to -$4.97. |
Employees: | 111 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$259.02M as of Dec 31, 2023 |
Net annual income (TTM): | -$260.49M as of Dec 31, 2023 |
Free cash flow (TTM): | -$195.61M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 52,508,602 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |